Patent Invalidation in Montreal.

A patent invalidation Montreal strategy starts with a structural fact that sets Canada apart from Europe and the United States: there is no patent office opposition to file. A Canadian patent, once granted by the Canadian Intellectual Property Office (CIPO), is presumed valid, and the only ways to knock it out are a Federal Court impeachment action, a validity defence or counterclaim inside an infringement suit, a challenge triggered by the patented-medicines linkage rules, or a CIPO re-examination confined to prior-art documents. For a company operating out of Montréal — the heart of Québec’s aerospace cluster, one of the world’s densest artificial-intelligence research hubs, and a base for pharma and video-game developers — the choice of route decides everything about how the prior art has to be built. PerspireIP assembles invalidity-grade prior-art searches for the accused manufacturers, generic entrants and technology firms who have to defeat a Canadian patent within this system.

Why patent invalidation Montreal cases run in the Federal Court

Canada gives the Federal Court a special role in patent validity. Under section 60 of the Patent Act, any interested person can bring an impeachment action asking the court to declare a patent, or any of its claims, invalid or void. A judgment of the Federal Court has effect across the whole country, so a successful impeachment removes the patent as an obstacle to the Canadian market in rem — not just between the two parties in the case. That national reach is why the Federal Court is the practical forum for a decisive, market-clearing validity attack.

Provincial superior courts — including the Québec Superior Court in Montréal — also have jurisdiction over patents, but with real limits. They can hear infringement claims and rule on validity as a defence, yet their judgments bind only the parties before them and carry no in rem effect. A patent found invalid in a provincial action still stands on the register against everyone else. In practice, almost all significant Canadian patent litigation is filed in the Federal Court, precisely because both sides want a validity ruling that settles the question nationally.

That structure raises the stakes on the prior art. A patent invalidation Montreal defendant who wants to clear the Canadian market cannot rely on a narrow, party-only outcome; the Federal Court attack has to be built to a standard that survives trial and the Federal Court of Appeal. The invalidity search is the foundation of the case, not a supporting exhibit, and it has to be charted, dated and ready before the pleadings close.

• Federal Court of Canada — national jurisdiction over patent impeachment and infringement; the forum of choice for in rem invalidity
• Québec Superior Court — can hear infringement and validity as a defence, but only inter partes and locally
• Federal Court of Appeal — hears appeals from Federal Court patent judgments
• CIPO re-examination board — the administrative, prior-art-only route to challenge granted claims

Four routes to challenge validity when Canada has no opposition

Unlike the European Patent Office or the U.S. Patent Trial and Appeal Board, CIPO runs no post-grant opposition and no inter partes review. There is no nine-month window to file an opposition, and no adversarial administrative trial in which a challenger cross-examines the patentee. That single fact reshapes strategy: in Canada, a third party who wants to attack a granted patent has four realistic paths, and each demands a different kind of prior-art package.

• Federal Court impeachment action — a standalone section 60 suit seeking a national declaration that the patent is invalid
• Validity defence or counterclaim — raised inside an infringement suit, so invalidity and infringement are tried together before one court
• PM(NOC) proceeding — a generic or biosimilar company puts validity in issue by serving a Notice of Allegation under the patented-medicines linkage rules
• CIPO re-examination — an administrative reconsideration of the claims, limited to prior-art patents, published applications and printed publications

The route governs the search. A re-examination request can rely only on documentary prior art — patents and printed publications — and cannot argue prior use, insufficiency or overbreadth. A Federal Court impeachment action or infringement counterclaim, by contrast, opens the full range of grounds and every category of evidence, from engineering literature to expert testimony on prior public use. Choosing the wrong forum for the prior art you actually have is a common and expensive mistake, and it is the first thing we help clients avoid.

Because there is no opposition to buy time, timing is unforgiving. A company that learns of a threatening Canadian patent has to decide quickly whether to strike first with an impeachment action, wait to be sued and counterclaim, or work the administrative re-examination route — and that decision should be driven by how strong, and how well-dated, the prior art already is.

The PM(NOC) linkage rules and Montreal pharma validity fights

The most concentrated stream of patent validity litigation in Canada flows through the Patented Medicines (Notice of Compliance) Regulations — the PM(NOC) or “linkage” system. When a generic or biosimilar manufacturer seeks a Notice of Compliance from Health Canada to sell a drug, it must address every patent the innovator has listed on the Patent Register against the reference product. To clear those patents, it serves a Notice of Allegation setting out, in detail, why each listed patent is invalid or would not be infringed.

A Notice of Allegation is, in substance, a written invalidity case delivered before the fight even starts. The innovator then has 45 days to bring a full action in the Federal Court, and that action is decided on the merits with a real trial — a structure introduced by the 2017 amendments that replaced the old summary “prohibition” applications. The result is that pharmaceutical validity in Canada is litigated squarely in the Federal Court, on a compressed timetable, with the prior art carrying the whole allegation.

For a generic entrant, the quality of the invalidity search is decisive twice over: first when drafting the Notice of Allegation, which must plead the anticipating or obviousness-defeating art with specificity, and again at trial, where the same references face expert cross-examination on novelty and inventive step. A vague or poorly-dated allegation invites the innovator to keep the generic off the market for the duration of the litigation. Montréal’s pharmaceutical and contract-manufacturing base makes these linkage disputes a recurring feature of Canadian dockets.

The decisive evidence in a pharma matter is rarely the headline patent. It lives in journal articles, formulation and dosage-regime disclosures, older abandoned families, regulatory documents and conference abstracts — sources an examiner is unlikely to have retrieved. We build that record and prove each reference’s public-availability date, so the allegation holds from service through to judgment.

CIPO re-examination: the administrative prior-art route

Not every validity challenge belongs in court. Sections 48.1 to 48.5 of the Patent Act let any person ask CIPO to re-examine the claims of a granted patent by filing prior art — limited to patents, published patent applications and printed publications — and paying the prescribed fee. The request must raise a substantial new question of patentability, meaning art the examiner did not already consider. The Commissioner then convenes a re-examination board, usually a Patent Appeal Board member chairing two senior examiners who had no hand in the original prosecution.

Re-examination is cheaper and faster than litigation, but it is deliberately narrow. The third-party requester’s involvement effectively ends once the request is filed; there is no cross-examination, no discovery, and no ability to argue prior use, insufficiency or overbreadth. The board can confirm, narrow or cancel claims on the documentary art alone. A Federal Court decision on validity, moreover, is not blocked by a re-examination and vice versa — the two tracks can run in parallel.

That makes re-examination a precision tool. It shines when a single, clean, well-dated document plainly anticipates a claim or renders it obvious, and the requester wants a low-cost route to narrow or kill the patent without committing to full-blown litigation. It is the wrong tool when the strongest attack depends on prior public use, on a complex obviousness combination that needs expert evidence, or on insufficiency. Matching the ground to the forum is exactly where a rigorous search pays off.

The grounds: anticipation, obviousness, insufficiency, overbreadth and utility

Canadian validity grounds are set by the Patent Act and decades of Federal Court and Supreme Court case law. A claim can fall for lack of novelty (anticipation) where a single prior disclosure discloses and enables the invention; for obviousness, assessed through the four-step Sanofi framework including the “obvious to try” inquiry; for insufficiency where the specification would not let a skilled person work the invention; for overbreadth where the claims are broader than the invention made or disclosed; and for lack of utility. Anticipation and obviousness dominate in practice, so the case turns on what was publicly available, and provably dated, before the claim date.

Utility deserves special mention because Canada’s law changed sharply. For years the courts applied a “promise doctrine” that let a patent be invalidated if it failed to deliver every use its disclosure could be read to promise. In AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36, the Supreme Court unanimously struck that doctrine down as an error of law. Today a mere scintilla of utility, demonstrated or soundly predicted by the filing date, satisfies section 2 — so utility rarely wins a case on its own, and the weight of the attack has shifted back to anticipation, obviousness, insufficiency and overbreadth.

Each ground rewards a different search. Anticipation needs one enabling document dated before the claim date; obviousness is built from a mosaic of references argued through Sanofi; insufficiency and overbreadth turn on comparing the claims against the disclosure and the common general knowledge. A search that ignores the ground the client will actually plead produces art that looks impressive and proves nothing at trial.

Montreal’s industries and where the decisive prior art lives

Montréal’s economy shapes the validity work that lands here. The city anchors one of the three largest aerospace clusters in the world, home to Bombardier, Pratt & Whitney Canada, CAE and Bell Textron Canada, so mechanical, avionics, materials and propulsion claims are a staple. It is also one of the planet’s densest deep-learning research hubs — the Mila institute, the legacy of Element AI and a concentration of machine-learning talent around Yoshua Bengio — which pushes a steady stream of AI and software patent disputes. Pharmaceutical developers and a large video-game sector led by Ubisoft round out the mix.

Each cluster invalidates on different evidence, and the killer reference is seldom the first patent a keyword search surfaces. Aerospace and mechanical claims often fall to engineering standards, technical manuals, SAE and AIAA papers and older machinery patents. AI and software claims turn on academic machine-learning literature, arXiv preprints, conference proceedings such as NeurIPS and ICML, and open-source repositories whose commit history fixes a public date. Pharma claims live in the journal, formulation and regulatory record; gaming and graphics claims in developer documentation, SDKs and prior game engines.

• Engineering standards, service manuals and SAE/AIAA papers for aerospace, propulsion and mechanical claims
• Machine-learning papers, arXiv preprints, NeurIPS/ICML proceedings and dated code repositories for AI and software claims
• Peer-reviewed journals, formulation and dosage disclosures and regulatory records for pharmaceutical and biosimilar claims
• Developer documentation, SDKs and prior game engines for gaming and computer-graphics claims
• Older and abandoned patent families used as anticipations or as obviousness combinations under Sanofi

A practical note on Québec: the province’s French-language commercial rules shape branding, marketing and packaging, and can matter to trademark and product-labelling strategy — but they do not change how patent validity is assessed. The Federal Court applies the same federal Patent Act and bilingual case law nationwide, so the language of a Montréal filing does not alter the invalidity analysis.

The other half of the work is proof of date. A reference only counts if it was genuinely public before the claim date, so we treat public-availability dating as evidence — capturing print dates, archive timestamps, indexing records and repository history that the Federal Court or a CIPO re-examination board can accept without argument.

How PerspireIP builds a patent invalidation Montreal case

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the claim date that actually governs each one, and search against that date rather than the grant date printed on the cover. For aerospace and mechanical subject-matter we combine patent art with standards, manuals and engineering literature; for AI and software we add academic papers, preprints and dated code; for pharma we run patent and deep non-patent-literature retrieval in parallel. Then we build claim charts a Federal Court judge or a re-examination board can follow line by line.

• Claim charting mapped to Canadian anticipation, the Sanofi obviousness framework, insufficiency and overbreadth
• Parallel patent and non-patent-literature searching tuned to aerospace, AI/software, pharma or gaming claims
• A read on the right forum — a section 60 Federal Court impeachment, an infringement counterclaim, a PM(NOC) Notice of Allegation, or a CIPO re-examination
• Public-availability dating evidenced for every reference, ready for the Federal Court or the re-examination board
• Prior art sized to the strategy, whether you strike first or defend and counterclaim

We work alongside your Canadian patent agents and litigation counsel as a specialist search partner, deliver to court and re-examination deadlines, and keep every engagement confidential. Whether you are an aerospace or technology manufacturer facing an infringement suit in the Federal Court, a generic drafting a Notice of Allegation, or counsel coordinating a national impeachment action, we scale to fit. Because Canada has no opposition to fall back on, the prior art is the case — send us the patent number and your key dates, and we will scope a patent invalidation Montreal project within one business day.

IP Landscape & Resources in Montreal

Key intellectual-property authorities and venues relevant to Montreal:

• Canadian Intellectual Property Office (CIPO) — the federal office that grants Canadian patents and administers re-examination under sections 48.1 to 48.5 of the Patent Act through a re-examination board
• Federal Court of Canada — the court with national jurisdiction over patent impeachment (section 60), infringement and PM(NOC) actions, whose validity judgments have in rem effect across Canada
• Patent Act (RSC 1985, c. P-4) — the governing statute; section 60 impeachment, sections 48.1 to 48.5 re-examination and the section 2 utility requirement clarified in AstraZeneca 2017 SCC 36
• Patented Medicines (Notice of Compliance) Regulations — the linkage regime under which a generic or biosimilar serves a Notice of Allegation putting listed-patent validity before the Federal Court

Request a Patent Invalidation Search in Montreal

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions